MedTrace Logo

Assessing the Impact of Control-IQ Technology

NCT04838561 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2022-01-21

No results posted yet for this study

Summary

This is a single-centre, mixed-methods, prospective study in pediatric patients with T1D initiating Control-IQ technology on the Tandem t-slim X2 insulin pump.

Primary Objective:

To determine pediatric T1D patients' and their parents' perceptions of the impact of Control-IQ on their psychosocial functioning and quality of life.

Conditions

Sponsors & Collaborators

  • Tandem Diabetes Care, Inc.

    collaborator INDUSTRY

  • Children's Hospital of Eastern Ontario

    lead OTHER

Principal Investigators

  • Caroline Zuijdwijk, MD, FRCPC · Children's Hopsital of Eastern Ontario

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-15
Primary Completion
2021-10-26
Completion
2021-10-26

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04838561 on ClinicalTrials.gov